Speaker Profile

Ph.D., SVP, TRC Immuno-Oncology and Cell Therapy, Research and Early Development, Bristol Myers Squibb

Teresa Foy is an immunologist with more than 25 years of biotechnology and pharmaceutical industry experience developing novel therapeutics in the areas of oncology and inflammation. At Bristol Myers Squibb, Teri leads the Immuno-Oncology and Cell Therapy Thematic Research Center. With a mission to drive leadership in the use of immune effector cell-based therapies in hematological and solid cancers, Teri and her team focus on the development and translation of BMS’ early I-O and cell therapy pipeline from discovery through human proof of concept. As part of her research, Teri also oversees close collaborations with other key research areas across the company, as well as external scientific partnerships.

 Session Abstract – PMWC 2022 Silicon Valley

For truly personalized cell and gene therapies to become standard of care, we must continue to leverage and successfully implement advances in science, technology, automation and digitization to scale the process and shorten the time it takes to get lifesaving medicines to patients in need.